Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
NCT04510610
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Hodgkin Lymphoma
Interventions
DRUG:
Camrelizumab and Decitabine
Sponsor
Chinese PLA General Hospital